DNA methylation in endometrial cancer: clinical potential in diagnosis and precision treatment

Introduction DNA methylation is a key epigenetic alteration in endometrial cancer (EC), offering a potential tool across multiple clinical domains. This review evaluates the level of clinical validation of DNA methylation-based biomarkers in EC. Methods We examined four areas: early detection and diagnostic triage; molecular subtyping and prognosis; hereditary triage in Lynch syndrome; and therapeutic decision-making, including chemoresistance, immunotherapy, PARP inhibitor response, and fertility preservation. Results Methylation-based assays using cervical scrapings, tampons or urine are promising for early detection and diagnostic triage in symptomatic or high-risk women, but they cannot replace histology and are not yet established for population screening. MLH1 promoter methylation testing is the only methylation assay with established clinical utility, serving as a triage step in mismatch repair deficiency (dMMR) EC and contributing to the differential diagnosis of sporadic versus Lynch syndrome-associated tumors. Methylation profiling may provide prognostic or biological insight within established molecular subtypes, such as risk assessment, resistance monitoring, and fertility-sparing decisions. However, evidence for MLH1 methylation as a predictor of immune checkpoint inhibitor response, BRCA1 methylation as a biomarker of PARP inhibitor sensitivity, and methylation markers for fertility-sparing decisions remains investigational and is derived largely from retrospective or cross-cancer data. Conclusion Assay standardization, pre-analytical and analytical variability, and the lack of large-scale prospective validation remain major barriers to clinical translation. By evaluating these biomarkers according to their level of clinical validation, this review aims to help clinicians understand the current evidence on DNA methylation in EC, its limitations, and its potential for future precision oncology.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-16
DOI
https://doi.org/10.3389/fonc.2026.1957758
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DNA methylation in endometrial cancer: clinical potential in diagnosis and precision treatment

Fang Chen, Hedi Ma
1 links
Frontiers in Oncology
Epigenetics and DNA Methylation
article

DNA methylation in endometrial cancer: clinical potential in diagnosis and precision treatment

Fang Chen, Hedi Ma
article en

Abstract

Introduction DNA methylation is a key epigenetic alteration in endometrial cancer (EC), offering a potential tool across multiple clinical domains. This review evaluates the level of clinical validation of DNA methylation-based biomarkers in EC. Methods We examined four areas: early detection and diagnostic triage; molecular subtyping and prognosis; hereditary triage in Lynch syndrome; and therapeutic decision-making, including chemoresistance, immunotherapy, PARP inhibitor response, and fertility preservation. Results Methylation-based assays using cervical scrapings, tampons or urine are promising for early detection and diagnostic triage in symptomatic or high-risk women, but they cannot replace histology and are not yet established for population screening. MLH1 promoter methylation testing is the only methylation assay with established clinical utility, serving as a triage step in mismatch repair deficiency (dMMR) EC and contributing to the differential diagnosis of sporadic versus Lynch syndrome-associated tumors. Methylation profiling may provide prognostic or biological insight within established molecular subtypes, such as risk assessment, resistance monitoring, and fertility-sparing decisions. However, evidence for MLH1 methylation as a predictor of immune checkpoint inhibitor response, BRCA1 methylation as a biomarker of PARP inhibitor sensitivity, and methylation markers for fertility-sparing decisions remains investigational and is derived largely from retrospective or cross-cancer data. Conclusion Assay standardization, pre-analytical and analytical variability, and the lack of large-scale prospective validation remain major barriers to clinical translation. By evaluating these biomarkers according to their level of clinical validation, this review aims to help clinicians understand the current evidence on DNA methylation in EC, its limitations, and its potential for future precision oncology.

Frontiers in OncologyVol. 16
Liaoning Provincial People's Hospital (CN)
Natural Science Foundation of Liaoning Province
Good health and well-being
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon